MA29317B1 - Composition contenant du chitosane pour une liberation prolongee de medicament - Google Patents

Composition contenant du chitosane pour une liberation prolongee de medicament

Info

Publication number
MA29317B1
MA29317B1 MA30195A MA30195A MA29317B1 MA 29317 B1 MA29317 B1 MA 29317B1 MA 30195 A MA30195 A MA 30195A MA 30195 A MA30195 A MA 30195A MA 29317 B1 MA29317 B1 MA 29317B1
Authority
MA
Morocco
Prior art keywords
composition containing
chitosan
containing chitosan
prolonged
release
Prior art date
Application number
MA30195A
Other languages
English (en)
Inventor
Adnan Badwan
Mayyas Mohammed Ahmad Al-Remawi
Murshed Abdel-Qader Mohammed
Original Assignee
Jordanian Pharmaceutical Mfg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jordanian Pharmaceutical Mfg filed Critical Jordanian Pharmaceutical Mfg
Publication of MA29317B1 publication Critical patent/MA29317B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L¿INVENTION CONCERNE UNE COMPOSITION POUR UNE LIBÉRATION PROLONGÉE DE MÉDICAMENT, COMPRENANT DU CHITOSANE DISSOUS DANS UN SOLVANT DONT LE PH EST INFÉRIEUR OU ÉGAL À 4,0 ENVIRON. CE CHITOSANE EST SÉLECTIONNÉ DANS LE GROUPE DE CHITOSANES DONT LE PRÉCIPITÉ TOMBE DANS UNE FOURCHETTE PH ALLANT DE 3,0 ENVIRON À 7,5 ENVIRON ; ET AU MOINS UN COMPOSÉ MÉDICAMENTEUX SOLUBLE DANS LADITE SOLUTION DE CHITOSANE.
MA30195A 2005-02-17 2007-09-06 Composition contenant du chitosane pour une liberation prolongee de medicament MA29317B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05003405A EP1693051B1 (fr) 2005-02-17 2005-02-17 Composition pour libération soutenue comprenant du chitosan

Publications (1)

Publication Number Publication Date
MA29317B1 true MA29317B1 (fr) 2008-03-03

Family

ID=34933799

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30195A MA29317B1 (fr) 2005-02-17 2007-09-06 Composition contenant du chitosane pour une liberation prolongee de medicament

Country Status (16)

Country Link
US (1) US20100130612A1 (fr)
EP (2) EP1693051B1 (fr)
JP (1) JP2008530148A (fr)
KR (1) KR20070104643A (fr)
CN (1) CN101128183A (fr)
AP (1) AP2007004156A0 (fr)
AT (1) ATE397439T1 (fr)
AU (1) AU2005327852A1 (fr)
BR (1) BRPI0520078A2 (fr)
CA (1) CA2598364A1 (fr)
DE (1) DE602005007319D1 (fr)
EA (1) EA200701735A1 (fr)
MA (1) MA29317B1 (fr)
TN (1) TNSN07288A1 (fr)
WO (1) WO2006087028A1 (fr)
ZA (1) ZA200706807B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1955693A1 (fr) * 2007-02-09 2008-08-13 The Jordanian Pharmaceutical Manufacturing Co. Composition comprenant du chitosan et un médicament acide pour une libération contrôlée orale
EP1955711A1 (fr) * 2007-02-09 2008-08-13 The Jordanian Pharmaceutical Manufacturing Co. Composition comprenant des conjugués covalent de chitosane et d'un médicament acide pour administration parentérale
DE102009024542A1 (de) * 2009-06-10 2010-12-16 Arivine Pharma Ag Zusammensetzungen auf Basis von Chitosan-Oligosacchariden

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8608890A1 (es) * 1985-09-16 1986-09-01 Carulla Vekar S A Preparado farmaceutico liquido a base de teofilina de efec- tos retardados y procedimiento para su obtencion
JPH05339149A (ja) * 1992-02-27 1993-12-21 Taisho Pharmaceut Co Ltd 徐放性懸濁製剤
US5422116A (en) * 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
JP3605613B2 (ja) * 2001-10-01 2004-12-22 有限会社関西キトサン 植物栽培用液剤
GB0302738D0 (en) * 2003-02-06 2003-03-12 Advanced Biopolymers As Composition

Also Published As

Publication number Publication date
EA200701735A1 (ru) 2008-02-28
EP1693051A1 (fr) 2006-08-23
US20100130612A1 (en) 2010-05-27
KR20070104643A (ko) 2007-10-26
ATE397439T1 (de) 2008-06-15
TNSN07288A1 (en) 2008-12-31
DE602005007319D1 (de) 2008-07-17
BRPI0520078A2 (pt) 2009-04-14
WO2006087028A1 (fr) 2006-08-24
CN101128183A (zh) 2008-02-20
EP1693051B1 (fr) 2008-06-04
CA2598364A1 (fr) 2006-08-24
AU2005327852A1 (en) 2006-08-24
JP2008530148A (ja) 2008-08-07
ZA200706807B (en) 2008-10-29
EP1848397A1 (fr) 2007-10-31
AP2007004156A0 (en) 2007-10-31

Similar Documents

Publication Publication Date Title
TN2010000073A1 (fr) Compositon pharmaceutique contenant un derive de benzene substitue par glucopyranosyle
TNSN01145A1 (fr) Derives d'imidazole a noyau aryle ou heteroaryle condense, et compositions les contenant.
MA29675B1 (fr) Nouvelle formulation pharmaceutique contenant un biguanide et un derive de thiazolidinedione
MA28722B1 (fr) Composition pharmaceutique orodispersible pour administration oromucosale ou sublinguale d'agomelatine.
TN2019000126A1 (fr) Nouvelles compositions antivirales pour le traitement des infections liées aux coronavirus.
SE0102764D0 (sv) Compounds
TNSN06037A1 (fr) Formulations liquides
SG165373A1 (en) Oral dosage form comprising an antimisuse system
PA8545101A1 (es) Sales tartrato de 5,8,14-triazatetraciclo [10.3.1.0 2,11 .0 4,9] hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas
MA29600B1 (fr) Utilisation de sanglifehrine dans le virus de l'hepatite c
WO2006044362A3 (fr) Antagonistes du recepteur 1 de n-sulfonylpiperidine cannabinoide
MA29324B1 (fr) Cetoenols cycliques substitues par spirocetal
MA29606B1 (fr) Combinaison pharmaceutique comprenant un antibacterien et une substance active choisie parmi le carveol, le thymol, l'eugenol, le borneol et le carvacrol
MA30766B1 (fr) Formes de dosage pharmaceutiques orales anti-manipulation contenant un analgesique opioide
WO2005072343A3 (fr) Compositions pharmaceutiques aqueuses de 2,6-diisopropylphenol (propofol) et leurs utilisations
MA28093A1 (fr) Forme polymorphe de 3-phenylsulfonyl-8-piperazine-1-yl-quinoleine
MA29543B1 (fr) Procedes pour traiter un cancer pharmacoresistant
FR2891460B1 (fr) Utilisation d'au moins un compose de la famille des avermectines pour le traitement des pathologies ophtalmiques dues au demodex folliculorum.
TNSN00108A1 (fr) Derives d'erythromycine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA29317B1 (fr) Composition contenant du chitosane pour une liberation prolongee de medicament
TNSN99001A1 (fr) Indoles 2,3-substitues servant d'agents anti-inflammatoires et analgesiques
WO2004064869A3 (fr) Agent de chelation metallique, a liaison amyloide
ATE459600T1 (de) Substituierte pyrrolidin-2-one
MA31775B1 (fr) Composé inhibiteur de la glycogène phosphorylase et composition pharmaceutique contenant ledit composé
FR2904774B1 (fr) Composition pharmaceutique solide contenant une combinaison d'un agent regulateur de la motilite intestinale et d'un antiflatulent.